Research suggests that glp-1 receptor agonists may reduce the risk of colorectal cancer in individuals with inflammatory bowel disease. Some reports indicate a link between glp-1 receptor agonists and lower colorectal cancer risk in patients with ibd, although the extent of this reduction is not consistently specified. The relationship between glp-1 receptor agonists and colorectal cancer risk in ibd populations appears to be an area of ongoing research and discussion.